Track market-moving stories before they get noisy

MetLife, Inc. (MET) Presents at KBW Insurance Conference 2026 Transcript

Key Takeaways MetLife's adjusted earnings rose 15% and total premium increased 5.8% in Q2 2026.MET is using AI, asset management and its New Frontier strategy to support scalable growth.MetLife's strong liquidity supports shareholder returns through share repurchases and dividend payouts. MetLife, Inc. (MET - Free Report) benefits from its diversified product portfolio, strong corporate relationships and global footprint, which support steady business volumes and premium growth. Its cost-cutting efforts, cash generation ability, strategic acquisitions and partnerships further support growth. Over the past year, shares of MET have grown 17.9%, outperforming the industry’s 4.6% rise.

MetLife — with a market capitalization of $62 billion — primarily provides protection and investment products to a range of individual and institutional customers. Beyond offering individual annuities, insurance and investment products, the company also delivers group insurance, as well as retirement and savings products and services. Its forward P/E of 9.30X is higher than the industry average of 9.17X.

Courtesy of solid prospects, MET currently carries a Zacks Rank #3 (Hold) and a Value Score of A.

MET’s Growth DriversMetLife continues to benefit from broad-based growth across its businesses, supported by stronger sales, favorable underwriting trends and improving operating momentum. Adjusted earnings rose 15% year over year to $1.6 billion in the second quarter of 2026, while total premium increased 5.8%.

Group Benefits remains an important contributor, supported by customer additions, broader product adoption and digital capabilities. MET continues to see strong opportunities in retirement and international markets. RIS-adjusted PFOs, excluding pension risk transfers, increased 19%, led by U.K. longevity reinsurance and structured settlement sales, while newer solutions such as U.K. FundedRe are broadening the platform. In Asia, sales climbed 17% on a constant-currency basis, helped by product launches and equity market tailwinds in Korea, while Latin America and EMEA sales rose 9% and 15%, respectively, creating additional room for expansion.

MET is also using technology and asset management to support scalable growth. AI-driven productivity gains are helping the company manage expenses while improving customer service and creating opportunities to apply data across policies, claims and service interactions. Meanwhile, MetLife Investment Management is expanding its role as the company grows its asset base and captures benefits from the integration of PineBridge.

MET’s New Frontier strategy combines capital-light and capital-driven businesses, leveraging its retirement origination, investment and risk-management capabilities to pursue growth while creating additional assets for its investment management platform. This model supports earnings diversification and more efficient capital deployment. The company also has flexibility to pursue additional growth through reinsurance, third-party capital and targeted acquisitions. Reinsurance can help MetLife originate more retirement business while creating additional assets for its investment management platform. The company is also evaluating selective opportunities in asset management and Group Benefits that can add complementary capabilities without requiring transformational deals.

MetLife’s robust liquidity position, evidenced by $19.3 billion in cash and cash equivalents as of June 30, 2026, far exceeds its short-term debt of $460 million. This financial strength supports shareholder returns through share repurchases and dividend payouts. The company bought back common shares worth $700 million in the second quarter of 2026. It pursued additional repurchases of roughly $225 million in July 2026. Its dividend yield of 2.5% remains higher than the industry’s average of 2.4%.

Where Do Estimates for MET Stand?The Zacks Consensus Estimate for MetLife’s 2026 earnings is pegged at $9.76 per share, indicating a 10.5% year-over-year rise, which has been revised upward over the past seven days. Furthermore, the consensus mark for revenues is pegged at $78.7 billion for 2026. It beat earnings estimates in each of the past four quarters, with an average surprise of 5.7%.

MET Stock: Risks to WatchHowever, there are some factors that investors should keep a careful eye on.

MET’s variable investment income has been volatile in recent years and remained below target at $1.5 billion in 2025. The first quarter of 2026 produced $518 million of pre-tax variable investment income, but the second quarter fell to $231 million due to lower private equity returns, and real estate and other fund returns.

The company’s return on invested capital (ROIC) is 1.9%, below the industry average of 2%. This indicates relatively weaker capital efficiency and modest returns on its investments.

Better-Ranked PlayersSome better-ranked stocks in the insurance space are Hippo Holdings Inc. (HIPO - Free Report) , Slide Insurance Holdings, Inc. (SLDE - Free Report) and The Hanover Insurance Group, Inc. (THG - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Hippo Holdings’ current-year earnings is pinned at $2.46 per share and has witnessed two upward revisions in the past 60 days against no movement in the opposite direction. HIPO beat earnings estimates in each of the trailing four quarters, with the average surprise being 521.8%. The consensus estimate for current-year revenues is pegged at $581.9 million, implying 24.2% year-over-year growth.

The Zacks Consensus Estimate for Slide Insurance Holdings’ current-year earnings is pinned at $3.79 per share and has witnessed two upward revisions in the past 60 days against one movement in the opposite direction. SLDE beat earnings estimates in each of the trailing four quarters, with the average surprise being 36.9%. The consensus estimate for current-year revenues is pegged at $1.5 billion, implying 29.5% year-over-year growth.

The Zacks Consensus Estimate for Hanover Insurance Group’s current-year earnings is pinned at $20.17 per share and has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. THG beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.3%. The consensus estimate for current-year revenues is pegged at $7 billion, implying 4.6% year-over-year growth.

Several industry giants that have seen impressive share price performance in 2026 recently made big-time buyback announcements. Share repurchases can do more than reduce share counts—they can also signal that management sees enough cash-flow strength and balance-sheet flexibility to keep returning capital after a strong run.

Three top firms have added $27 billion in buyback capacity, indicating confidence in their outlooks and cash generation. This includes a $14 billion authorization from one of the best-performing stocks of 2026, which has cemented itself as a critical player in AI infrastructure.

Get Sandisk alerts:

SanDisk Signals Continued Confidence After Hallmark Run in 2026Sandisk Stock Forecast Today12-Month Stock Price Forecast:
$1,999.27
25.26% Upside

Buy
Based on 26 Analyst Ratings

Current Price$1,596.08High Forecast$3,050.00Average Forecast$1,999.27Low Forecast$322.00Sandisk Stock Forecast Details

The insatiable demand for NAND flash solid-state drives (SSDs) from AI customers has led to huge revenue increases and margin expansion at SanDisk NASDAQ: SNDK. Notably, SanDisk’s revenue rose 372% year-over-year (YOY) last quarter, while its adjusted gross margin increased more than 5,800 basis points to just under 85%.

Aside from this incredible financial performance, the company also made one of the most notable buyback announcements within the AI trade over recent months. SanDisk has announced an additional $14 billion share buyback program, bringing its total buyback capacity to $15.5 billion. The company’s capacity is equal to more than 6% of its market capitalization, a sizable figure.

This announcement is particularly notable due to the huge returns SanDisk has generated. The stock is up more than 500% in 2026—making SanDisk the best-performing large-cap stock in the United States. The company noted at its recent Investor Day that it will return 100% of its excess cash to shareholders. As SanDisk does not pay a dividend, this will come through buybacks

In turn, SanDisk is indicating that it plans to spend billions on buybacks even after the astonishing rise in its share price. This signals considerable confidence going forward and can allow the company to add a meaningful tailwind to per-share metrics.

Phillips 66 Profit Soars, Adds $10 Billion in Buyback CapacityPhillips 66 Stock Forecast Today12-Month Stock Price Forecast:
$206.56
-15.12% Downside

Moderate Buy
Based on 22 Analyst Ratings

Current Price$243.34High Forecast$255.00Average Forecast$206.56Low Forecast$147.00Phillips 66 Stock Forecast Details

Although not as stunning as SanDisk’s 2026 gain, oil giant Phillips 66 NYSE: PSX has also put up an extremely strong performance, up more than 80%. The company generated adjusted earnings of $3.8 billion in its latest quarter, up from just $207 million in Q1.

Notably, margins on refined products are soaring. Disruptions in the Middle East have not only damaged the worldwide supply of crude oil, but also that of refined products like gasoline. This comes as significant refining capacity resides in the Middle East.

In turn, refineries that continue to operate, like those in the United States, benefit from the imbalance of supply and demand. Notably, crack spreads on diesel fuel, which measures the difference between the price of crude and refined diesel, recently moved above $100 for the first time ever.

As Phillip’s profits surge, the company is adding big-time buyback capacity to return capital to shareholders. The company has approved a $10 billion buyback program, equal to more than 10% of its market capitalization.

Given the lack of progress in Iran and U.S. negotiations, industry analysts do not expect the prices of refined products to fall drastically anytime soon. Phillip’s buyback program indicates confidence in its cash flow generation amid this, while refining imbalances could support strong earnings for some time.

MetLife Lifts Buyback Capacity by $3 Billion, Supporting Further Share Count ReductionsMetLife Stock Forecast Today12-Month Stock Price Forecast:
$101.64
7.63% Upside

Moderate Buy
Based on 14 Analyst Ratings

Current Price$94.44High Forecast$109.00Average Forecast$101.64Low Forecast$90.00MetLife Stock Forecast Details

MetLife NYSE: MET is one of the largest players in the United States insurance industry, with a market capitalization of nearly $60 billion. The stock has also been one of the better performers in its industry during the year, delivering a total return near 20%. Notably, MetLife achieved solid adjusted earnings growth of 15% YOY in its latest report.

Meanwhile, adjusted earnings per share grew considerably faster at 20% YOY. This demonstrates the beneficial effect of MetLife’s share buybacks, which came in at $722 million during the quarter, moderately lowering its share count.

MetLife has since re-upped its buyback capacity, recently announcing a $3 billion incremental authorization. This lifts MetLife’s total buyback capacity to $3.4 billion, equal to more than 5% of its market capitalization. Although its buyback spending has fluctuated considerably over time, MetLife has delivered value to shareholders by steeply dropping its share count. Over the past five years, MetLife’s outstanding shares have fallen by approximately 25%.

MetLife’s latest authorization gives the firm considerable firepower to continue lowering its outstanding shares and adding a tailwind to per-share metrics as it did in Q2.

SanDisk Stands Out as NAND Demand and AI Growth AccelerateAll three companies are signaling confidence through larger buyback authorizations, but Sandisk may offer the most compelling combination of growth and capital returns.

SanDisk isn’t alone in showing continued confidence in its outlook; Wall Street analysts are doing the same. The MarketBeat consensus price target for SanDisk sits just below $2,000, implying more than 20% upside in the shares. Looking ahead, it will be important to monitor how the supply-and-demand imbalance in NAND flash products evolves.

Notably, some analysts expect the NAND Flash market to become slightly oversupplied in the second half of 2027. This could potentially reduce SanDisk’s pricing power. However, a large wave of agentic AI adoption could put the market closer to equilibrium.

Phillips 66 and MetLife offer more mature capital-return stories, but Sandisk’s combination of AI-driven growth, expanding profitability and a commitment to return excess cash could give it the most upside if NAND demand remains strong. Nonetheless, these dynamics are difficult to forecast, making continued monitoring of updates and management commentary key.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Sandisk Right Now?Before you consider Sandisk, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandisk wasn't on the list.

While Sandisk currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

EP Wealth Advisors LLC acquired a new position in shares of MetLife, Inc. (NYSE:MET – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,942 shares of the financial services provider’s stock, valued at approximately $1,857,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Commonwealth Retirement Investments LLC boosted its position in shares of MetLife by 0.5% in the 4th quarter. Commonwealth Retirement Investments LLC now owns 26,953 shares of the financial services provider’s stock worth $2,128,000 after purchasing an additional 131 shares in the last quarter. CreativeOne Wealth LLC grew its stake in shares of MetLife by 1.3% in the 4th quarter. CreativeOne Wealth LLC now owns 10,156 shares of the financial services provider’s stock worth $802,000 after buying an additional 135 shares during the last quarter. Kathmere Capital Management LLC increased its position in MetLife by 2.4% during the 1st quarter. Kathmere Capital Management LLC now owns 5,813 shares of the financial services provider’s stock valued at $411,000 after buying an additional 136 shares in the last quarter. Worth Asset Management LLC raised its stake in MetLife by 3.1% during the second quarter. Worth Asset Management LLC now owns 4,551 shares of the financial services provider’s stock valued at $385,000 after buying an additional 138 shares during the last quarter. Finally, Bleakley Financial Group LLC raised its stake in MetLife by 0.5% during the fourth quarter. Bleakley Financial Group LLC now owns 29,687 shares of the financial services provider’s stock valued at $2,343,000 after buying an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In MET has been the topic of a number of recent research reports. Weiss Ratings raised MetLife from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, June 15th. UBS Group lifted their price target on MetLife from $102.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Keefe, Bruyette & Woods upped their price target on shares of MetLife from $105.00 to $108.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 11th. Wells Fargo & Company increased their price objective on shares of MetLife from $101.00 to $109.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Barclays raised their price objective on shares of MetLife from $94.00 to $97.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $101.64.

Get Our Latest Research Report on MET Trending Headlines about MetLife Here are the key news stories impacting MetLife this week:

Positive Sentiment: Wall Street Zen upgraded MetLife to a Buy rating, providing a favorable near-term sentiment catalyst for MetLife, Inc. (NYSE: MET). MetLife Upgraded by Wall Street Zen to Buy Rating Positive Sentiment: Dowling & Partners issued a positive outlook for MetLife’s earnings, reinforcing expectations for continued operating strength. This view follows the company’s latest reported quarter, when earnings per share exceeded consensus estimates and revenue increased year over year. DOWLING & PARTN Issues Positive Outlook for MetLife Earnings Neutral Sentiment: A review of life-insurance companies’ second-quarter results benchmarks MetLife (NYSE: MET) against its industry peers. The article may help investors assess relative performance, but the headline does not identify a new company-specific catalyst. Life Insurance Stocks Q2 Recap: Benchmarking MetLife Neutral Sentiment: Multiple articles cover Bruno Mars’ concerts, schedules, weather, ticket availability and fan experience at MetLife Stadium. Although potentially relevant to the stadium’s venue business, MetLife, Inc. is an insurance and financial-services company; the stadium’s naming rights do not make these events a material direct driver of MET shares. Bruno Mars Opens Four Nights at MetLife Tonight MetLife Trading Up 1.0% Shares of NYSE:MET opened at $94.44 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.20 and a quick ratio of 0.20. MetLife, Inc. has a 1 year low of $67.33 and a 1 year high of $100.93. The company has a market cap of $60.77 billion, a P/E ratio of 18.09, a PEG ratio of 0.73 and a beta of 0.78. The stock’s fifty day moving average price is $92.41 and its 200-day moving average price is $82.17.

MetLife (NYSE:MET – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The financial services provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.30 by $0.13. MetLife had a return on equity of 23.39% and a net margin of 4.57%.The company had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $19.67 billion. During the same period last year, the company earned $2.02 EPS. MetLife’s revenue for the quarter was up 10.5% on a year-over-year basis. Sell-side analysts expect that MetLife, Inc. will post 9.72 earnings per share for the current year.

MetLife Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 4th will be paid a $0.5925 dividend. The ex-dividend date is Tuesday, August 4th. This represents a $2.37 dividend on an annualized basis and a dividend yield of 2.5%. MetLife’s payout ratio is currently 45.40%.

MetLife declared that its Board of Directors has authorized a share buyback plan on Wednesday, August 5th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the financial services provider to buy up to 4.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

About MetLife (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Featured Stories Five stocks we like better than MetLife 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET – Free Report).

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.31471411 per share on the company's floating rate noncumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: MET PRA). Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarte.

NEW YORK--(BUSINESS WIRE)--MetLife Pet Insurance today announced a partnership with America's VetDogs, a national nonprofit that provides service dogs to veterans, first responders and active-duty service members at no cost, to sponsor the dogs' training and development so that it will one day support a veteran or first responder living with a disability.

Can Trupanion Turn Pet Insurance Loyalty Into Real Earnings?MetLife NYSE: MET reported second-quarter 2026 adjusted earnings of approximately $1.6 billion, or $2.43 per share, up 15% from a year earlier. Adjusted earnings per share increased 20%, while adjusted return on equity reached 17%, the top end of the company’s 15% to 17% annual target range.

Get MetLife alerts:

President and Chief Executive Officer Michel Khalaf said the results reflected the execution of MetLife’s “New Frontier” strategy, which combines capital-light businesses such as Group Benefits, international operations and asset management with capital-driven retirement and spread-based operations.

The “Duck Stock” Keeps Quietly Making Money for Shareholders“Adjusted earnings increased in every business segment compared with a year ago,” Khalaf said, citing strong underwriting, broad volume growth and continued capital returns to shareholders.

Capital Returns and Expense Management MetLife repurchased about $700 million of common shares during the quarter and returned more than $2.4 billion to shareholders through July through buybacks and common dividends. The company also announced a new $3 billion share repurchase authorization.

These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Holding-company cash and liquid assets totaled $3.4 billion at June 30, within MetLife’s stated target buffer of $3 billion to $4 billion. Chief Financial Officer and Head of MetLife Investment Management John McCallion said the company returned approximately $1.1 billion to shareholders in the second quarter, including the share repurchases, and bought an additional roughly $225 million of shares in July.

The direct expense ratio was 12.1% in the quarter, compared with 11.7% in the year-ago quarter and for full-year 2025. The ratio included an approximately 50-basis-point impact from the addition of PineBridge Investments, which has a structurally higher expense profile. Management said it remains on track to beat its 12.1% full-year 2026 target through expense discipline and productivity initiatives.

Khalaf said artificial intelligence is becoming a structural advantage for the company because of the volume of policies, customer interactions and claims MetLife handles. He said the company monitors AI-related investment and usage costs under the same return standards applied to other investments and expenses.

Group Benefits Leads Segment Growth Group Benefits generated adjusted earnings of $503 million, up 25% year over year, supported by favorable life underwriting and volume growth. The group life mortality ratio was 79%, better than the company’s 2026 target range of 83% to 88%, reflecting improved mortality trends among the working-age population.

Ramy Tadros, president of MetLife’s U.S. business, said the quarter included about two points of mortality favorability from prior-period development and lower-than-expected claim severity. He said the company expects those factors to normalize during the remainder of the year, with early indications evident in July results.

Tadros said any longer-term normalization of Group Life margins would occur gradually because the business has a three- to five-year renewal cycle. Year-to-date Group Benefits sales rose 9%, including an 11% increase in regional business. Adjusted premiums, fees and other revenues increased 4% excluding participating contracts.

Non-Medical Health’s interest-adjusted benefit ratio was 73.9%, within its 70% to 75% annual target range and 190 basis points better sequentially. Tadros said paid family and medical leave claims followed the anticipated pattern of higher claims early in a program’s rollout before moderating. He also cited favorable disability results, driven by experience and investments in data analytics and AI intended to improve recoveries.

Retirement, International Operations and Asset Management Retirement & Income Solutions, or RIS, recorded adjusted earnings of $377 million, up 2% from the prior year. Adjusted premiums, fees and other revenues excluding pension risk transfers increased 19%, led by U.K. longevity reinsurance and structured settlement sales.

RIS reported a total investment spread of 97 basis points, below management’s 100- to 120-basis-point guidance range because of weaker private-equity returns in variable investment income. Core spread excluding variable investment income was 100 basis points, up 5 basis points sequentially. McCallion said MetLife expects its core RIS spread to remain within a 95- to 100-basis-point range and estimated third-quarter results could be near the midpoint because of real estate income seasonality.

Management described the U.S. pension risk transfer market as lighter in the first half, particularly for jumbo transactions, but said it sees a stronger opportunity pipeline for the second half. Tadros said MetLife sold nearly $14 billion of pension risk transfers in 2025, including $12 billion in the fourth quarter, illustrating the market’s uneven timing. He added that MetLife wrote more than $1 billion of U.K. funded reinsurance year to date.

Asia adjusted earnings rose 21% on a reported basis and 25% on a constant-currency basis to $420 million. Sales increased 17% on a constant-currency basis, supported by Korea and product launches. In Japan, sales rose 2% from a strong year-earlier comparison and 13% sequentially, while accident and health sales grew nearly 90% on a constant-currency basis following a medical product launch.

Latin America posted a quarterly record of $268 million in adjusted earnings, up 15% reported and 4% on a constant-currency basis. Sales rose 9% on the same basis, with growth led by Brazil, Mexico and Chile. EMEA adjusted earnings increased 8%, or 11% on a constant-currency basis, to $108 million, while sales rose 15% on a constant-currency basis.

MetLife Investment Management, or MIM, generated adjusted earnings of $57 million, up 6%, as PineBridge integration and expense management contributed to results. Total assets under management rose $12 billion sequentially to approximately $748 billion at June 30, including a $7 billion increase in institutional client assets. McCallion said MIM remains positioned to deliver full-year adjusted earnings within its $240 million to $280 million guidance range, though likely near the low end.

M&A and Investment Positioning During the question-and-answer session, Khalaf said MetLife’s approach to acquisitions has not changed. He identified asset management and Group Benefits as the areas most likely to be considered for acquisitions, emphasizing complementary capabilities and adjacencies rather than transformational transactions.

McCallion said MetLife expects its private-equity allocation to decline modestly over time as distributions from its seasoned portfolio outpace contributions, though the company will continue investing in the asset class. He said higher interest rates can provide positive momentum over time, but portfolio changes are incremental and governed by asset-liability management and risk considerations.

About MetLife (NYSE:MET)MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in MetLife Right Now?Before you consider MetLife, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.

While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Key Takeaways MET beat EPS estimates as adjusted operating earnings rose 20% year over year on strong investment income.MetLife saw growth across Group Benefits, Asia and EMEA, supported by underwriting and business volume.MET repurchased $700 million of shares in Q2 and maintained its near-term adjusted ROE target of 15-17%. MetLife, Inc. (MET - Free Report) reported second-quarter 2026 adjusted operating earnings per share (EPS) of $2.43, which beat the Zacks Consensus Estimate by 5.6%. The bottom line advanced 20% year over year.

Adjusted operating revenues improved 6.4% year over year to $19.1 billion. The top line missed the consensus mark by 1.4%.

MetLife’s second-quarter earnings benefited from improved net investment income, favorable underwriting results and solid business volume growth across segments. Growth in adjusted PFOs and strong performances in Group Benefits, Asia and EMEA also supported results. However, higher expenses and a wider-than-expected loss in the Corporate & Other unit partially offset the upside.

Behind the Q2 HeadlinesAdjusted PFOs, excluding pension risk transfer (PRT), were $13 billion. The metric rose 5% year over year.

Adjusted net investment income grew 7% year over year to $5.6 billion on the back of growth in assets and investments in a higher-rate environment.

Total expenses of $18.1 billion escalated 10.8% year over year due to increased policyholder benefits and claims, and other expenses, net of capitalization of DAC. Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT, deteriorated 100 basis points year over year to 20.8%.

Net income of $705 million rose 1% year over year in the second quarter. Adjusted return on equity, excluding total notable items, improved 240 bps year over year to 17%.

Inside MetLife’s SegmentsGroup Benefits: The segment reported adjusted earnings of $503 million in the second quarter, reflecting a 25% year-over-year increase and beating the Zacks Consensus Estimate by 16.6%. The strong performance was driven by improved underwriting results and continued business volume growth. Adjusted PFOs rose 1% year over year to $6.5 billion.

RIS: Adjusted earnings totaled $377 million, which rose 2% year over year but missed the consensus mark by 7.1%. Improved volumes growth and favorable recurring interest margins benefited the metric. Adjusted PFOs, excluding PRT, advanced 19% year over year to $1.3 billion.

Asia: The unit recorded adjusted earnings of $420 million, which rose 21% year over year and beat the Zacks Consensus Estimate by 5.2%. The metric was supported by improved variable investment income, favorable equity markets and higher volume. Adjusted PFOs remained flat year over year to $1.7 billion in the quarter.

Latin America: Adjusted earnings of $268 million increased 15% year over year on a reported basis and 4% year over year on a constant-currency basis. The metric topped the consensus estimate by 11.2%, driven by higher volume and favorable market factors. Adjusted PFOs were $1.9 billion, up 16% year over year on a reported basis and 6% on a constant-currency basis, driven by solid business growth and strong persistency across the region.

EMEA: The segment recorded adjusted earnings of $108 million in the second quarter, which advanced 8% year over year and beat the Zacks Consensus Estimate by 15.3%. Strong volumes aided the metric. Adjusted PFOs rose 12% year over year to $806 million on the back of strong policy renewal across the region and solid sales momentum.

MetLife Investment Management: The segment recorded adjusted earnings of $57 million, which advanced 6% year over year on the back of strong business growth and expense management. However, the metric missed the Zacks Consensus Estimate by 6.1%.

Corporate & Other: The unit incurred an adjusted loss of $160 million, wider than the prior-year quarter’s loss of $142 million. It also came higher than the Zacks Consensus Estimate of adjusted loss of $150.5 million.

Financial Update (as of June 30, 2026)MetLife exited the second quarter with cash and cash equivalents of $19.3 billion, down from $22 billion at the end of 2025. Total assets were $759.4 billion as of June 30, 2026, compared with $745.2 billion as of 2025-end.

Long-term debt totaled $14.2 billion, lower than $14.5 billion at the end of 2025, while short-term debt amounted to $460 million.

Total equity was $27.7 billion compared with $28.7 billion as of 2025-end. Book value per share increased 7.8% year over year to $38.59 as of June 30, 2026.

Capital Deployment UpdateMetLife bought back shares worth $700 million in the second quarter. It pursued additional repurchases of roughly $225 million in July 2026. Management paid common stock dividends of $400 million in the quarter under review.

MET’s 2026 OutlookManagement earlier expected a pre-tax variable investment income of around $1.6 billion for 2026. The expense ratio was earlier projected to be 12.1%.

Corporate & Other adjusted losses were earlier projected to be between $500 million and $700 million. The effective tax rate was projected to be 24-26%.

Near-Term TargetsMetLife earlier expected adjusted PFOs in the Group Benefits business to rise in the range of 4-7% annually. Adjusted PFOs in the Latin America unit were earlier expected to witness high-single-digit growth on a constant-currency basis, while those in the EMEA unit were earlier guided to grow at a high-single-digit rate on a reported basis.

MetLife still aims to achieve an adjusted return on equity in the range of 15-17%. The company also continues to expect to deliver double-digit adjusted EPS growth in the near term.

MET’s Zacks RankMET currently has a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

How Did Peers Perform?Here are some stocks from the broader insurance space that have also reported their quarterly results: RenaissanceRe Holdings Ltd. (RNR - Free Report) , Aon plc (AON - Free Report) and The Hartford Insurance Group, Inc. (HIG - Free Report) . Here's how they have performed:

RenaissanceRe reported second-quarter 2026 operating income of $12.92 per share, which surpassed the Zacks Consensus Estimate by 12.9%.  The bottom line also improved 5.1% year over year. Total operating revenues declined 6.7% year over year to $2.64 billion. The quarterly earnings benefited from lower expenses, higher net investment income and an improved total combined ratio. However, RNR’s upside was partly offset by lower net premiums earned, weaker underwriting results in the Casualty & Specialty segment and lower fee income.

Aon reported second-quarter 2026 adjusted earnings of $3.81 per share, which surpassed the Zacks Consensus Estimate by 1.1%. The bottom line advanced 9% year over year. Total revenues of $4.2 billion grew 2% year over year. AON’s quarterly results were supported by strong organic revenue growth, healthy client retention, operating margin expansion and disciplined execution. Solid performance across the Commercial Risk, Reinsurance and Health Solutions businesses was partly offset by weakness in Wealth Solutions.

Hartford delivered second-quarter fiscal 2026 earnings per share of $3.42, up 6% year over year and above the Zacks Consensus Estimate of $3.12 by 9.6%. Revenues came in at $5.23 billion, which improved 6.8% year over year. HIG’s quarterly results benefited from higher investment income, premium growth in Business Insurance and improving Personal Insurance profitability. Strong new business expansion in Small Business and favorable pricing trends supported results. However, the upside was partly offset by an increased expense level, higher catastrophe losses and weaker Employee Benefits profitability.

For the quarter ended June 2026, MetLife (MET - Free Report) reported revenue of $19.08 billion, up 6.4% over the same period last year. EPS came in at $2.43, compared to $2.02 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $19.34 billion, representing a surprise of -1.38%. The company delivered an EPS surprise of +5.65%, with the consensus EPS estimate being $2.30.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how MetLife performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Institutional Client AUM: $320.46 billion versus $346.62 billion estimated by three analysts on average.Total AUM: $748.13 billion compared to the $741.21 billion average estimate based on three analysts.METLIFE INVESTMENT MANAGEMENT(MIM)-GA AUM: $427.67 billion compared to the $394.59 billion average estimate based on three analysts.Adjusted Revenue- Corporate & other- Net investment income: $944 million versus the three-analyst average estimate of $974.37 million. The reported number represents a year-over-year change of +1309%.Adjusted Revenue- Corporate & other- Premiums: $596 million compared to the $637.33 million average estimate based on three analysts. The reported number represents a change of +7350% year over year.Adjusted Revenue- EMEA- Net investment income: $67 million versus the three-analyst average estimate of $67.41 million. The reported number represents a year-over-year change of +9.8%.Adjusted Revenue- Latin America- Net investment income: $587 million versus $440.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +31.9% change.Revenue- Premiums: $11.44 billion versus $11.97 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change.Revenue- Other Revenues: $845 million compared to the $742.31 million average estimate based on four analysts. The reported number represents a change of +24.5% year over year.Revenue- Net investment income: $6.7 billion versus $5.5 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +18.4% change.Revenue- Universal life and investment-type product policy fees: $1.37 billion versus $1.32 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9% change.Adjusted Revenue- Retirement & Income Solutions- Premiums: $1.59 billion versus $2.03 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +31.2% change.View all Key Company Metrics for MetLife here>>>

Shares of MetLife have returned +4.9% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and chief financial officer, and head of MetLife Investment Management, has provided a second quarter 2026 financial update video. The video can be viewed on the company's website at https://www.metlife.com/about-us/newsroom/#video. About MetLife MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world's leading financial services companie.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that its board of directors has approved a new $3 billion authorization for the company to repurchase its common stock. The new authorization is incremental to the approximately $400 million remaining under the company's prior authorization announced in April 2025. “This new share repurchase authorization reflects our confidence in MetLife's long-term outlook and continued ability to generate capital,” said MetLife President a.

Key Takeaways MET is expected to post Q2 EPS growth of 13.9% on 7.9% higher revenue year over year.MetLife may benefit from growth in Group Benefits and Retirement & Income Solutions results.MET's Q2 premiums are projected to increase 10.7% year over year. Insurance provider MetLife, Inc. (MET - Free Report) is set to report its second-quarter 2026 results on Aug. 5, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $2.30 per shareon revenues of $19.34 billion.

The second-quarter earnings estimate witnessed six upward revisions and no movement in the opposite direction over the past 60 days. The bottom-line projection indicates a year-over-year increase of 13.9%. Also, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 7.9%.

Image Source: Zacks Investment Research

For full-year 2026, the Zacks Consensus Estimate for MetLife’s revenues is pegged at $79.33 billion, implying a decline of 0.6% year over year. However, the consensus mark for 2026 EPS is pegged at $9.89, implying 12% year-over-year growth.

MetLife beat earnings estimates in three of the past four quarters and missed once, with the average surprise being 2.4%. This is depicted in the figure below.

Q2 Earnings Whispers for MetLifeOur proven model predicts a likely earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is precisely the case here.

MET has an Earnings ESP of +0.66% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

You can see the complete list of today’s Zacks #1 Rank stocks here.

What’s Shaping MetLife’s Q2 Results?The Zacks Consensus Estimate for second-quarter premiums indicates a 10.7% year-over-year increase. While the consensus mark signals 3.3% growth in Group Benefits adjusted revenues, the same from Retirement & Income Solutions is projected to jump 28% in the second quarter.

The consensus estimate indicates a 10.3% year-over-year increase in adjusted earnings from the Retirement & Income Solutions segment and 7.9% growth in adjusted earnings from the Group Benefits unit. MetLife Investment Management’s adjusted earnings are pegged at $60.7 million. Further, adjusted earnings from Asia are expected to grow 14.1% year over year and 3.4% from the Latin America business.

These are likely to have positioned the company for year-over-year growth and an earnings beat. The positives are likely to be partially offset by a 2.8% decline in net investment income. Also, adjusted earnings from the EMEA region are expected to decline 6.3% year over year.

How Did Other Insurers Fare This Quarter?Several insurance companies, including Marsh & McLennan Companies, Inc. (MRSH - Free Report) , AMERISAFE, Inc. (AMSF - Free Report) and RenaissanceRe Holdings Ltd. (RNR - Free Report) , have already reported their financial results for the June quarter of 2026. Here’s how they performed:

Marsh reported second-quarter 2026 adjusted earnings per share of $2.96, which surpassed the Zacks Consensus Estimate by 2.8%. The bottom line advanced 8.8% year over year.Its strong quarterly results benefited from solid growth in the Risk and Insurance Services and Consulting units. However, the upside was partially offset by Marsh’s elevated operating expenses, primarily due to increased compensation and benefits.

AMERISAFE reported second-quarter adjusted earnings per share of 44 cents, missing the Zacks Consensus Estimate by 17%. The bottom line also declined 17% year over year. The quarterly result was affected by higher expenses and weaker underwriting margins, with additional pressure from lower investment income. AMSF’s strong premium growth partly offset these headwinds.

RenaissanceRe reported second-quarter 2026 operating income of $12.92 per share, which surpassed the Zacks Consensus Estimate by 12.9%. The bottom line also improved 5.1% year over year. The quarterly earnings benefited from lower expenses, higher net investment income and an improved total combined ratio. However, the upside was partly offset by lower net premiums earned, weaker underwriting results in RNR’s Casualty & Specialty segment and lower fee income.

Analysts on Wall Street project that MetLife (MET - Free Report) will announce quarterly earnings of $2.30 per share in its forthcoming report, representing an increase of 13.9% year over year. Revenues are projected to reach $19.34 billion, increasing 7.9% from the same quarter last year.

Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

With that in mind, let's delve into the average projections of some MetLife metrics that are commonly tracked and projected by analysts on Wall Street.

Analysts forecast 'Revenue- Other Revenues' to reach $742.31 million. The estimate suggests a change of +9.3% year over year.

The combined assessment of analysts suggests that 'Revenue- Net investment income' will likely reach $5.50 billion. The estimate suggests a change of -2.8% year over year.

The consensus among analysts is that 'Revenue- Universal life and investment-type product policy fees' will reach $1.32 billion. The estimate points to a change of +4.7% from the year-ago quarter.

According to the collective judgment of analysts, 'Revenue- Premiums' should come in at $11.97 billion. The estimate suggests a change of +10.7% year over year.

Analysts predict that the 'Total Adjusted Revenue- Latin America' will reach $2.25 billion. The estimate suggests a change of +8.5% year over year.

Analysts' assessment points toward 'Adjusted Revenue- Corporate & other- Net investment income' reaching $974.37 million. The estimate indicates a year-over-year change of +1354.3%.

The consensus estimate for 'Total Adjusted Revenue- EMEA' stands at $846.38 million. The estimate indicates a year-over-year change of +8.5%.

The collective assessment of analysts points to an estimated 'Total Adjusted Revenue- Asia' of $3.11 billion. The estimate points to a change of +7% from the year-ago quarter.

It is projected by analysts that the 'Adjusted Revenue- Asia- Net investment income' will reach $1.39 billion. The estimate indicates a year-over-year change of +14.6%.

Based on the collective assessment of analysts, 'Adjusted Revenue- EMEA- Net investment income' should arrive at $67.41 million. The estimate suggests a change of +10.5% year over year.

Analysts expect 'Adjusted Revenue- Latin America- Net investment income' to come in at $440.74 million. The estimate indicates a change of -1% from the prior-year quarter.

The average prediction of analysts places 'Adjusted Revenue- Asia- Other Revenues' at $17.76 million. The estimate points to a change of -19.3% from the year-ago quarter.

View all Key Company Metrics for MetLife here>>>

Over the past month, shares of MetLife have returned +7.8% versus the Zacks S&P 500 composite's -0.5% change. Currently, MET carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

MetLife Investment Management (“MIM”), the institutional asset management business of MetLife, Inc. (NYSE: MET), together with development partner ZOM Livi

Posted by Defense World Staff on Jul 20th, 2026

Boston Common Asset Management LLC trimmed its position in MetLife, Inc. (NYSE:MET – Free Report) by 11.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,516 shares of the financial services provider’s stock after selling 13,810 shares during the quarter. Boston Common Asset Management LLC’s holdings in MetLife were worth $7,745,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in MetLife by 9.0% during the fourth quarter. Brighton Jones LLC now owns 4,240 shares of the financial services provider’s stock valued at $347,000 after buying an additional 351 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of MetLife in the first quarter worth $307,000. Empowered Funds LLC raised its stake in shares of MetLife by 187.6% in the 1st quarter. Empowered Funds LLC now owns 33,378 shares of the financial services provider’s stock valued at $2,680,000 after acquiring an additional 21,771 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of MetLife in the 2nd quarter valued at $404,000. Finally, Jump Financial LLC acquired a new position in shares of MetLife during the 2nd quarter valued at $444,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

MetLife Stock Performance NYSE:MET opened at $93.99 on Monday. The firm has a 50-day moving average of $85.80 and a two-hundred day moving average of $79.07. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.20 and a quick ratio of 0.20. The stock has a market cap of $60.48 billion, a P/E ratio of 18.21, a PEG ratio of 0.72 and a beta of 0.78. MetLife, Inc. has a 1-year low of $67.33 and a 1-year high of $94.86.

MetLife (NYSE:MET – Get Free Report) last announced its earnings results on Wednesday, May 6th. The financial services provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.15. MetLife had a return on equity of 22.60% and a net margin of 4.66%.The business had revenue of $14.18 billion for the quarter, compared to analyst estimates of $19.49 billion. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.96 earnings per share. On average, research analysts expect that MetLife, Inc. will post 9.94 earnings per share for the current fiscal year.

MetLife Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 4th will be issued a dividend of $0.5925 per share. The ex-dividend date is Tuesday, August 4th. This represents a $2.37 annualized dividend and a yield of 2.5%. MetLife’s payout ratio is currently 45.93%.

Wall Street Analysts Forecast Growth A number of analysts recently weighed in on the stock. Morgan Stanley upped their price target on shares of MetLife from $93.00 to $103.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Bank of America cut their price objective on MetLife from $103.00 to $99.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Wall Street Zen cut MetLife from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings raised MetLife from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, June 15th. Finally, Keefe, Bruyette & Woods increased their target price on MetLife from $98.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.57.

Check Out Our Latest Report on MetLife

Key Stories Impacting MetLife Here are the key news stories impacting MetLife this week:

Positive Sentiment: MetLife Stadium is hosting the World Cup final, which keeps the venue in the global spotlight and may highlight the company’s high-profile asset and brand visibility. FIFA insists MetLife Stadium’s pitch is ready for the World Cup final despite criticism Positive Sentiment: Heavy media coverage around ticket sales, fan guides, food and drink pricing, and kickoff details suggests strong interest and traffic around the event at MetLife Stadium. How to buy tickets to see Spain in World Cup Final at MetLife Neutral Sentiment: News about weather, heat, storms, air quality, and wildfire smoke could affect the event experience, but it does not directly change MetLife’s earnings outlook. World Cup final could be shaped by heat, storms and air quality at MetLife Stadium Neutral Sentiment: FIFA’s criticism of the pitch and the “money grab” controversy may create headline risk for the venue, but the impact on MetLife’s stock is likely limited unless the issue affects operations or reputation more broadly. NJ governor slams FIFA’s money grab over sales of MetLife World Cup pitch Negative Sentiment: Ongoing criticism about the field quality and pitch conditions at MetLife Stadium could dent the venue’s reputation, even though it is unlikely to materially affect MetLife’s insurance business. The MetLife trap: the controversial pitch threatening the final | OneFootball MetLife Profile (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Read More Five stocks we like better than MetLife Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMicron Technology, Inc. $MU Holdings Lowered by Boston Common Asset Management LLC

Key Takeaways MetLife is embedding AI across core operations to improve efficiency and customer experiences.MET invested $3.2 billion in technology over five years to support enterprise-wide AI adoption.MET's Q1 2026 adjusted EPS rose 23.5% YoY, while its direct expense ratio improved to 11.9%. MetLife, Inc. (MET - Free Report) is increasingly embedding artificial intelligence (AI) across its business as part of its New Frontier strategy, with the goal of improving efficiency, enhancing customer experiences and supporting long-term growth. Rather than treating AI as a standalone initiative, the insurer is integrating the technology into core operations, from underwriting and claims to customer service and decision-making. This approach is helping the company simplify workflows while positioning it to compete more effectively in an evolving insurance market.

MetLife has invested more than $3.2 billion over the past five years to modernize its technology infrastructure. These investments are enabling broader AI adoption across the enterprise. AI tools are helping employees make faster decisions, reduce operational friction and deliver more personalized customer interactions. MetLife continues to emphasize responsible AI deployment through robust governance and risk management practices.

The company's AI investments are already supporting stronger operating performance. In the first quarter of 2026, adjusted earnings per share (EPS) increased 23.5% year over year to $2.42. At the same time, MetLife's direct expense ratio, excluding total notable items related to direct expenses and PRT, improved to 11.9% from 12% a year ago, reflecting continued productivity gains and disciplined cost management.

AI is becoming more than an operational tool for MetLife — it is evolving into a strategic differentiator. By combining technology-driven efficiency with disciplined execution and a diversified business model, the company is positioning itself to improve productivity, strengthen customer relationships and build a sustainable competitive advantage over the long run.

How Are Competitors Faring?Some of MET’s competitors adopting AI to improve operations include American International Group, Inc. (AIG - Free Report) and CNO Financial Group, Inc. (CNO - Free Report) .

AIG is expanding its use of AI to improve underwriting accuracy, automate claims handling and strengthen risk assessment. American International Group is also using generative AI to support employees and streamline workflows, helping improve operational efficiency while delivering faster and more personalized customer service.

CNO Financial is adopting AI and advanced analytics to modernize customer engagement, automate routine processes and improve agent productivity. CNO is also investing in digital capabilities that simplify policy servicing and support more personalized insurance solutions, strengthening its long-term operating efficiency.

MET’s Price Performance, Valuation & EstimatesIn the year-to-date period, MET’s shares have risen 17.3% compared with the industry’s growth of 4.9%.

Image Source: Zacks Investment Research

From a valuation standpoint, MET trades at a forward price-to-earnings ratio of 8.80, above the industry average of 8.27. MetLife carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for MET’s 2026 earnings implies 13% growth from the year-ago period.

Image Source: Zacks Investment Research

MetLife currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that its board of directors has declared a third quarter 2026 common stock dividend of $0.5925 per share. The dividend will be payable on September 8, 2026, to shareholders of record as of August 4, 2026. About MetLife MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management.

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that Chris Aiken has been appointed head of Real Estate Equity Strategies, effective immediately. He will report to Andrea Drasites, global head of Real Estate and Agricultural Finance.

“Chris is an integral part of our real estate platform and has consistently demonstrated strong leadership skills, deep market expertise and a commitment to delivering value for our clients,” said Brian Funk, president of MIM. “His experience across acquisitions, development and portfolio strategy, combined with his collaborative style, positions him well to lead our Real Estate Equity Strategies business as we continue to advance the platform.”

As head of Real Estate Equity Strategies, Aiken will lead MIM’s direct property investment platform and oversee investing activities on behalf of MetLife’s general account and third-party institutional investors across core, core-plus, build-to-core, value-add and opportunistic strategies.

MIM’s real estate portfolio represented $106.2 billion in assets under management as of March 31, 2026.1 The announcement follows the appointment of Andrea Drasites as global head of Real Estate and Agricultural Finance, reflecting the firm’s continued investment in its real estate capabilities and leadership team as it expands its global platform.

Prior to assuming this role, Aiken served as head of Acquisitions for MIM’s Real Estate Equity Strategies Group. Before joining MIM, he was a Managing Director at Safanad, where he led all aspects of the investment lifecycle across multiple real estate strategies. He also held real estate investment roles at BlackRock and Salomon Smith Barney.

Aiken earned an M.S. in Real Estate Finance from New York University and a B.A. in Business Administration from Morehouse College. He is a member and co-chair of the Membership Committee for the Real Estate Executive Council and a member of the Urban Land Institute’s Urban Development Mixed-Use Council.

About MetLife Investment Management

MetLife Investment Management, the institutional asset management business of MetLife, Inc. (NYSE: MET), provides tailored investment management solutions to institutional investors worldwide. MetLife Investment Management has long-established global expertise in public fixed income, private fixed income, real estate, equity, alternatives, multi-asset, and insurance solutions and provides public and private pension plans, insurance companies, endowments, funds and other institutional clients with a range of bespoke investment solutions that seek to meet a range of long-term investment objectives and risk-adjusted returns over time. MetLife Investment Management has over 150 years of investment experience and, as of March 31, 2026, had $736.3 billion in total assets under management. For more information, see MetLife Investment Management’s Total Assets Under Management fact sheet for the quarter ended March 31, 2026 available on MetLife’s Investor Relations web page (https://investor.metlife.com).

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit https://www.metlife.com.

Forward-Looking Statements

The forward-looking statements in this news release, using words such as “continue,” “positions,” “seek” and “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements.

1 At estimated fair value. Mortgage loans, real estate and real estate joint ventures are included at net asset value, net of deduction for encumbering debt and have been adjusted from carrying value to estimated fair value.

NEW YORK--(BUSINESS WIRE)--For many pet parents, saying goodbye to a beloved dog or cat is one of life’s most difficult experiences. MetLife Pet Insurance is introducing a new Memorial Tree Program to help honor that bond, alongside grief counseling services that support pet parents through end-of-life decisions and the months that follow.

MetLife Pet Insurance is introducing a new Memorial Tree Program to help honor pets, alongside grief counseling services that support pet parents through end-of-life decisions.

Share MetLife Pet Insurance research underscores the depth of that bond: 95% of Americans consider their pet to be family, and 50% say they have grieved a pet’s death more deeply than a human loved one, underscoring the need for support that addresses both the emotional and practical aspects of loss.

Through a collaboration with the National Forest Foundation, MetLife Pet Insurance will honor every insured pet that passes away by supporting the planting of a tree in a U.S. National Forest. Policyholders who cancel coverage due to the death of a pet will receive a sympathy card noting that a memorial tree will be planted in their pet’s honor.

The program builds on MetLife Pet Insurance’s existing grief counseling services, provided by TELUS Health, which connect eligible policyholders with trained counselors for guidance during end-of-life decisions and in the months that follow.

“Pets are family, and the loss of a pet can be one of the most emotional experiences a person can face,” said Brian Jorgensen, head of MetLife Pet Insurance. “We’re focused on showing up for pet parents during that time, not only by helping them honor their pets, but by offering support when they need it most.”

The initiative reflects a broader focus on emotional well-being across MetLife’s offerings. Through its group life offerings, MetLife also provides grief counseling and emotional wellness services through TELUS Health as part of the MetLife Advantages program, reinforcing a consistent approach to care across life and pet insurance.

The National Forest Foundation leads one of the largest reforestation efforts in the United States, restoring forests impacted by wildfire, disease and other environmental challenges.

The Memorial Tree Program is expected to launch in June 2026.

About MetLife Pet Insurance Solutions, LLC

MetLife Pet coverage is issued by Metropolitan General Insurance Company, a Rhode Island insurance company headquartered at 700 Quaker Lane, Warwick, RI 02886. MetLife Pet Insurance Solutions LLC is the policy administrator. It may operate under an alternate or fictitious name in certain jurisdictions, including MetLife Pet Insurance Services LLC (New York and Minnesota) and MetLife Pet Insurance Solutions Agency LLC (Illinois). For more information, visit https://www.metlifepetinsurance.com.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com. 

More News From MetLife, Inc.

-

Opening represents a revitalized era of seamless travel and economic investment for Greater Montreal

LONGUEUIL, Quebec--(BUSINESS WIRE)--Porter Airlines is launching its first flights from Montreal Metropolitan Airport - MET, a significant, privately-funded national transportation infrastructure project, located in Longueuil on Montreal’s South Shore. The airport’s close proximity to downtown will meaningfully contribute to increasing air access for one of Canada’s most prominent cities. Four inaugural routes begin today: with Vancouver, Toronto-Pearson, Toronto-City, and St. John’s, N.L.

Over the next week, Porter is introducing flights to 11 airports across the country from MET, just in time for the summer travel season. Passenger traffic at MET is projected to hit one million in its first year, climbing to four million annually at full capacity.

MET routes*

Start date

Frequency

St. John’s (YYT) **

June 15

7x weekly

Toronto City (YTZ)

June 15

27x weekly

Toronto Pearson (YYZ)

June 15

20x weekly

Vancouver (YVR)

June 15

14x weekly

Edmonton (YEG)

June 16

7x weekly

Calgary (YYC)

June 17

7x weekly

Halifax (YHZ)

June 17

14x weekly

Charlottetown (YYG) **

June 18

7x weekly

Winnipeg (YWG) **

June 18

7x weekly

Moncton (YQM) **

June 19

7x weekly

Hamilton (YHM)

June 22

14x weekly

  *Note: MET’s official airport designation code is YHU
**Seasonal route

Flights can be booked at www.flyporter.com and through travel agencies.

This launch marks a historic moment for Montreal’s air travel sector, offering Montrealers and visitors greater flexibility for travelling throughout Canada. Improved air connectivity also strengthens Montreal’s economic development, stimulating trade and business opportunities.

With new service from MET and continued operations at Montreal-Trudeau Airport, Porter is set to nearly double its capacity in Greater Montreal this summer, adding over 1,000 flights. Moreover, a partnership with Pascan Aviation will boost regional connections across Quebec, the Maritimes, and Porter’s broader North American network.

Porter is recognized as one of North America’s top airlines, known for its refined, attentive service and complimentary amenities. This includes premium snacks, a selection of beverages, including beer and wine served in glassware, and fast, free WiFi on its E195-E2 aircraft.

MET will be served by Porter’s fleet of De Havilland Dash 8-400s (78 seats) and Embraer E195-E2s (132 seats), which are among the quietest and most fuel-efficient aircraft in their respective classes. Both feature a two-by-two seating configuration, with no middle seats, for enhanced comfort.

Quotes

“Starting new routes is something that we often do, but launching 11 at once from a new airport to transform a city’s connectivity is exceptional. This is truly meaningful for Montreal’s people, economy and tourism, and we’re proud to be a part of it. Demand is already exceeding our expectations, and as soon as travellers discover Porter’s unique offering, combined with MET’s comfort and convenience, they will have a new appreciation for air travel.”

- Michael Deluce, CEO, Porter Airlines

“This new terminal is the result of a collaborative process involving citizens and elected officials, a process that began long before the ground-breaking ceremony. Today, we are proud to see that 80% of the population on Montreal’s South Shore supports the MET project.”

- Simon-Pierre Diamond, interim president of MET – Montreal Metropolitan Airport

“We are proud to welcome Porter Airlines to YHU Terminal at MET- Montreal Metropolitan Airport and to support the expansion of its network in Greater Montreal. Together, we are offering travellers an experience that combines Porter’s renowned service with a terminal specifically designed to provide a faster, more seamless and more comfortable journey from curb to gate.”

- Charles Roberge, president and Chief Executive Officer, YHU Terminal

About Porter

Since 2006, Porter Airlines has been elevating the experience of economy air travel for every passenger, providing genuine hospitality with style, care and charm. Porter’s fleet of Embraer E195-E2 and De Havilland Dash 8-400 aircraft serves North America, including a coast-to-coast domestic Canadian network, the U.S., Mexico, the Caribbean and Central America. Headquartered in Toronto, Porter is an Official 4 Star Airline® in the World Airline Star Rating®. Visit www.flyporter.com or follow @porterairlines on Instagram, Facebook and X.

More News From Porter Airlines

Back to Newsroom

MarketBeat Instant News Alerts

2 hours ago

Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of StockMarketBeat

MarketAxess Holdings Inc. (NASDAQ:MKTX - Get Free Report) General Counsel Scott Pintoff sold 100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $116.03, for a total transaction of $11,603.00. Following the transaction, the general counsel owned 11,786 shares in the company, valued at approximately $1,367,529.58. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:MKTX

Read Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of Stock

Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 327

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.

The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

When we join a positive earnings ESP with a Zacks Rank #3 (Hold) or stronger, stocks posted a positive bottom-line surprise 70% of the time. Plus, this system saw investors produce roughly 28% annual returns on average, according to our 10 year backtest.

Stocks with a #3 (Hold) ranking, which is most stocks covered at 60%, are expected to perform in-line with the broader market. But stocks that fall into the #2 (Buy) and #1 (Strong Buy) ranking, or the top 15% and top 5% of stocks, respectively, should outperform the market. Strong Buy stocks should outperform more than any other rank.

Should You Consider Bank of Montreal?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Bank of Montreal (BMO - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $2.47 a share 13 days away from its upcoming earnings release on May 27, 2026.

Bank of Montreal's Earnings ESP sits at +1.51%, which, as explained above, is calculated by taking the percentage difference between the $2.47 Most Accurate Estimate and the Zacks Consensus Estimate of $2.43. BMO is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

BMO is part of a big group of Finance stocks that boast a positive ESP, and investors may want to take a look at MetLife (MET - Free Report) as well.

Slated to report earnings on August 5, 2026, MetLife holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $2.46 a share 83 days from its next quarterly update.

For MetLife, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $2.45 is +0.11%.

Because both stocks hold a positive Earnings ESP, BMO and MET could potentially post earnings beats in their next reports.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

MetLife delivers robust adjusted income, supporting a bullish stance on common shares and fixed-rate preferreds. MET's preferred dividend payout ratio remains low, with $24.5B in common equity providing strong downside protection for preferred holders. Series A floating-rate preferreds yield 5.45%-5.5%, attractive if short-term rates rise, but fixed-rate Series F offers a higher current yield.

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerPR Newswire

CHICAGO, May 29, 2026

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomesASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations, /PRNewswire/ -- Johnson & Johnson NYSE:JNJ today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypical epidermal growth factor receptor (EGFR) mutations. The analysis showed encouraging long-term outcomes with RYBREVANT® plus LAZCLUZE® in this difficult-to-treat population. Median overall survival, a secondary endpoint, was nearly 3.5 years.1 The primary endpoint of objective response rate was previously reported.2 These results add to the growing body of evidence demonstrating the potential of RYBREVANT® plus LAZCLUZE® to deliver durable survival outcomes across both common and atypical EGFR-mutated advanced NSCLC in the first-line setting. Data were presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #8501).1

Significant unmet need in patients with atypical EGFR-mutated NSCLCPatients with atypical EGFR-mutated NSCLC tend to have poorer outcomes than those with common EGFR mutations (exon 19 deletions and L858R substitutions), and effective first-line treatment options remain limited.3,4 These mutations represent approximately 10-20 percent of all EGFR-mutated cases.5 Median overall survival with current standard of care single-agent therapies remains under two years, highlighting a significant unmet need for treatments that can deliver more durable benefit in this setting.6,7 RYBREVANT® is designed to dual target EGFR and mesenchymal-epithelial transition (MET), while engaging the immune system.8,9,10,11 These complementary mechanisms play a central role in tumor growth and treatment resistance and may help address the underlying drivers of disease.Expert and company perspectives supporting the strength of RYBREVANT® plus LAZCLUZE®"For patients with non-small cell lung cancer harboring atypical EGFR-mutations, first-line treatment decisions are often clouded by uncertainty regarding the efficacy of currently available EGFR tyrosine kinase inhibitors," said Joel Neal,* M.D., Ph.D., principal investigator of the Phase 1/1b CHRYSALIS-2 study. "The responses we've seen in this trial suggest the potential for more durable disease control, and the overall survival data reinforce that picture. These long-term outcomes begin to change how we think about treatment options in managing this subtype of lung cancer." Neal is also a Professor of Medicine in the Division of Oncology at Stanford Medicine."Disease progression and molecular resistance remain critical barriers in EGFR-mutated non-small cell lung cancer," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "RYBREVANT-based combinations demonstrate the power of changing the biology by addressing multiple disease drivers from the start rather than relying on single-pathway strategies. With strong outcomes across all known EGFR mutations, this approach is raising the bar for what first-line treatment can achieve."Detailed CHRYSALIS-2 study resultsIn Cohort C of the CHRYSALIS-2 study, RYBREVANT® plus LAZCLUZE® was evaluated as a first-line treatment in patients with atypical EGFR-mutated advanced NSCLC, excluding EGFR exon 20 insertion mutations (n=49). The most common atypical EGFR mutations included G719X (55 percent), S768X (27 percent) and L861X (24 percent), with 35 percent of patients harboring multiple atypical mutations. The study previously reported an objective response rate of 57 percent (primary endpoint).1,2Median overall survival with RYBREVANT® plus LAZCLUZE® reached nearly 3.5 years (41.0 months; 95 percent confidence interval [CI], 27.7-not estimable) at a median follow-up of 31.3 months. Overall survival rates were 55 percent at three years and 46 percent at four years.1Consistent clinical activity was observed across atypical EGFR mutation subgroups, as well as across patient and disease characteristics such as central nervous system metastases and TP53 status. Patients were also able to remain on treatment long-term across mutation groups and baseline characteristics. Notably, 41 percent of patients remained on RYBREVANT® for two years or longer, further supporting the durable survival observed with this combination.1The safety profile of RYBREVANT® plus LAZCLUZE® was consistent with previous reports, with no new safety signals observed with longer follow-up. Most adverse events were Grade 1 or 2. The most common treatment-emergent adverse events occurring in more than 30 percent of patients included paronychia (78 percent), rash (65 percent), hypoalbuminemia (61 percent) and infusion-related reactions (61 percent).1RYBREVANT®-based regimens are approved for patients with EGFR-mutated advanced NSCLC across common (exon 19 deletions and exon 21 L858R substitution mutations) and exon 20 insertion mutations, including in the first-line setting.12 These results further define long-term outcomes with first-line RYBREVANT® plus LAZCLUZE® for patients with atypical EGFR mutations. Additional data being presented at ASCO 2026 in lung, head and neck, and colorectal cancers underscore the broader potential of RYBREVANT® across tumor types.About the CHRYSALIS-2 StudyCHRYSALIS-2 (NCT04077463) is an open-label Phase 1/1b study to evaluate the safety and pharmacokinetics of LAZCLUZE®, a third-generation EGFR-TKI, as monotherapy or in combinations with RYBREVANT®, a human bispecific EGFR and cMet antibody in participants with advanced NSCLC. The study enrolled 460 patients with advanced NSCLC.13Cohort C of the ongoing CHRYSALIS-2 study evaluates patients with atypical EGFR-mutated advanced NSCLC, excluding exon 20 insertion and classical EGFR mutations, who are treatment-naïve or have received up to two prior lines of therapy. Patients received intravenous RYBREVANT® in combination with LAZCLUZE® administered orally once daily.13About Non-Small Cell Lung Cancer Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.14,15 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.16 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.17 EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.14,15,18,19,20,21 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.22 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.23,24 EGFR exon 20 insertion mutations are the third-most prevalent activating EGFR mutation.25 Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.26About RYBREVANT®RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved in these populations and can be used as monotherapy or in combination with LAZCLUZE® (lazertinib) or chemotherapy in the front- and second-line settings, offering convenient monthly† or bi-weekly dosing. RYBREVANT FASPRO™ is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.RYBREVANT® (amivantamab-vmjw), administered intravenously, received U.S. FDA approval in March 2024 and is approved for the same indications as RYBREVANT FASPRO™ across multiple markets. RYBERVANT® is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.The effectiveness of RYBREVANT FASPRO™ is supported by the established clinical profile of RYBREVANT®, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE® in first-line advanced EGFR-mutated NSCLC.The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)‡ 27 include amivantamab-vmjw (RYBREVANT®) across its FDA-approved treatment settings, including as a Category 1 preferred option in combination with lazertinib (LAZCLUZE®) for first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) may be substituted for IV amivantamab-vmjw (RYBREVANT®) where appropriate. See the latest NCCN Guidelines® for NSCLC for complete information.§ ||The NCCN Guidelines for Central Nervous System Cancers also include amivantamab (RYBREVANT®)-based regimens, including in combination with lazertinib (LAZCLUZE®), as the only NCCN-preferred combination options for patients with EGFR-mutated NSCLC and brain metastases.§ ||Beyond NSCLC, RYBREVANT-based therapies are being investigated across other solid tumors, including head and neck and colorectal cancers.The legal manufacturer for RYBREVANT® is Janssen Biotech, Inc. For more information, visit www.rybrevanthcp.com.About LAZCLUZE®In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE® (marketed as LECLAZA in South Korea). LAZCLUZE® is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR. An analysis of the efficacy and safety of LAZCLUZE® from the Phase 3 LASER301 study was published in The Journal of Clinical Oncology in 2023.28The legal manufacturer for LAZCLUZE® is Janssen Biotech, Inc. and Yuhan Corporation.INDICATIONSRYBREVANT® (amivantamab-vmjw) is indicated:

in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.IMPORTANT SAFETY INFORMATION FOR RYBREVANT FASPRO™ AND RYBREVANT® 12,29CONTRAINDICATIONSRYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.WARNINGS AND PRECAUTIONS Hypersensitivity and Administration-Related Reactions with RYBREVANT FASPRO™ RYBREVANT FASPRO™ can cause hypersensitivity and administration-related reactions (ARR); signs and symptoms of ARR include dyspnea, flushing, fever, chills, chest discomfort, hypotension, and vomiting. The median time to ARR onset is approximately 2 hours.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade ARR occurred in 13% of patients, including 0.5% Grade 3. Of the patients who experienced ARR, 89% occurred with the initial dose (Week 1, Day 1).

Premedicate with antihistamines, antipyretics, and glucocorticoids and administer RYBREVANT FASPRO™ as recommended. Monitor patients for any signs and symptoms of administration-related reactions during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt RYBREVANT FASPRO™ injection if ARR is suspected. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO™ based on severity.Infusion-Related Reactions with RYBREVANT®RYBREVANT® can cause infusion-related reactions (IRR) including anaphylaxis; signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), IRRs occurred in 63% of patients, including Grade 3 in 5% and Grade 4 in 1% of patients. IRR-related infusion modifications occurred in 54%, dose reduction in 0.7%, and permanent discontinuation of RYBREVANT® in 4.5% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population (n=281), IRRs occurred in 50% of patients including Grade 3 (3.2%) adverse reactions. IRR-related infusion modifications occurred in 46%, and permanent discontinuation of RYBREVANT® in 2.8% of patients.

RYBREVANT® as a Single Agent

In CHRYSALIS (n=302), IRRs occurred in 66% of patients. IRRs occurred in 65% of patients on Week 1 Day 1, 3.4% on Day 2 infusion, 0.4% with Week 2 infusion, and were cumulatively 1.1% with subsequent infusions. 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after start of infusion. IRR-related infusion modifications occurred in 62%, and permanent discontinuation of RYBREVANT® in 1.3% of patients.Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs. Monitor patients for signs and symptoms of IRRs in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity. If an anaphylactic reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/Pneumonitis RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, ILD/pneumonitis occurred in 6% of patients, including Grade 3 in 1%, Grade 4 in 1.5%, and fatal cases in 1.9% of patients. 5% of patients permanently discontinued RYBREVANT FASPRO™ and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT® and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ILD/pneumonitis occurred in 2.1% of patients with 1.8% of patients experiencing Grade 3 ILD/pneumonitis. 2.1% discontinued RYBREVANT® due to ILD/pneumonitis.

RYBREVANT® as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) permanently discontinued RYBREVANT® due to ILD/pneumonitis.Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® (when applicable) in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.Venous Thromboembolic (VTE) Events with Concomitant Use with LAZCLUZE®RYBREVANT FASPRO™ and RYBREVANT® in combination with LAZCLUZE® can cause serious and fatal venous thromboembolic (VTE) events, including deep vein thrombosis and pulmonary embolism. Without prophylactic anticoagulation, the majority of these events occurred during the first four months of treatment.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade VTE occurred in 11% of patients and 1.5% were Grade 3. 80% (n=164) of patients received prophylactic anticoagulation at study entry, with an all Grade VTE incidence of 7%. In patients who did not receive prophylactic anticoagulation (n=42), all Grade VTE occurred in 17% of patients. In total, 0.5% of patients had VTE leading to dose reductions of RYBREVANT FASPRO™ and no patients required permanent discontinuation. The median time to onset of VTEs was 95 days (range: 17 to 390).

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), VTEs occurred in 36% of patients including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT®, and 7% of patients had VTE leading to dose interruptions of LAZCLUZE®; 1% of patients had VTE leading to dose reductions of RYBREVANT®, and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE®; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT®, and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE®. The median time to onset of VTEs was 84 days (range: 6 to 777).Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT FASPRO™ or RYBREVANT®. Treatment can continue with LAZCLUZE® at the same dose level at the discretion of the healthcare provider. Refer to the LAZCLUZE® Prescribing Information for recommended LAZCLUZE® dosage modification.Dermatologic Adverse ReactionsRYBREVANT FASPRO™ and RYBREVANT® can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus and dry skin.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, rash occurred in 80% of patients, including Grade 3 in 17% and Grade 4 in 0.5% of patients. Rash leading to dose reduction occurred in 11% of patients, and RYBREVANT FASPRO™ was permanently discontinued due to rash in 1.5% of patients.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, rash occurred in 86% of patients, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT® and 30% for LAZCLUZE®, rash leading to dose reductions occurred in 23% of patients for RYBREVANT® and 19% for LAZCLUZE®, and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT® and 1.7% for LAZCLUZE®.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, rash occurred in 82% of patients, including Grade 3 (15%) adverse reactions. Rash leading to dose reductions occurred in 14% of patients, and 2.5% permanently discontinued RYBREVANT® and 3.1% discontinued pemetrexed.

RYBREVANT® as a Single Agent

In CHRYSALIS, rash occurred in 74% of patients, including Grade 3 in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% and permanent discontinuation due to rash occurred in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%).When initiating treatment with RYBREVANT FASPRO or RYBREVANT and LAZCLUZE, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic adverse reactions. Instruct patients to limit sun exposure during and for 2 months after treatment. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen.If skin reactions develop, administer supportive care including topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® in combination with LAZCLUZE®, withhold, reduce the dose, or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® based on severityHepatotoxicityLAZCLUZE® in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).

RYBREVANT® with LAZCLUZE®

In MARIPOSA, based on adverse reaction data, hepatotoxicity occurred in 49% of patients treated with LAZCLUZE®, including Grade 3 in 9.3% of patients and Grade 4 in 0.5%. LAZCLUZE® was interrupted for an adverse reaction of hepatotoxicity in 8% of patients, the dose was reduced in 1.4% and permanently discontinued in 0.2%.Perform liver function tests (including ALT, AST, and total bilirubin) before initiation of LAZCLUZE® and during treatment, as clinically indicated. Withhold, reduce the dose, or permanently discontinue LAZCLUZE® and amivantamab based on severity.Ocular ToxicityRYBREVANT FASPRO™ and RYBREVANT® can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus and uveitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, all Grade ocular toxicity occurred in 13% of patients, including 0.5% Grade 3.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ocular toxicity occurred in 16%, including Grade 3 or 4 ocular toxicity in 0.7% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ocular toxicity occurred in 16% of patients. All events were Grade 1 or 2.

RYBREVANT® as a Single Agent

In CHRYSALIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients. All events were Grade 1-2.Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® and continue LAZCLUZE® based on severity.Embryo-Fetal ToxicityBased on animal models, RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE® can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating RYBREVANT FASPRO™ and RYBREVANT®. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT FASPRO™ or RYBREVANT®, and for 3 weeks after the last dose of LAZCLUZE®.ADVERSE REACTIONSRYBREVANT FASPRO™ with LAZCLUZE®In PALOMA-3 (n=206), the most common adverse reactions (≥20%) were rash (80%), nail toxicity (58%), musculoskeletal pain (50%), fatigue (37%), stomatitis (36%), edema (34%), nausea (30%), diarrhea (22%), vomiting (22%), constipation (22%), decreased appetite (22%), and headache (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocyte count (6%), decreased sodium (5%), decreased potassium (5%), decreased albumin (4.9%), increased alanine aminotransferase (3.4%), decreased platelet count (2.4%), increased aspartate aminotransferase (2%), increased gammaglutamyl transferase (2%), and decreased hemoglobin (2%).Serious adverse reactions occurred in 33% of patients, with those occurring in ≥2% of patients including ILD/pneumonitis (6%); and pneumonia, VTE and fatigue (2.4% each). Death due to adverse reactions occurred in 5% of patients treated with RYBREVANT FASPRO™, including ILD/pneumonitis (1.9%), pneumonia (1.5%), and respiratory failure and sudden death (1% each).RYBREVANT® with LAZCLUZE®In MARIPOSA (n=421), the most common adverse reactions (ARs) (≥20%) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT®) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and IRRs (RYBREVANT®) (2.1% each). Fatal ARs occurred in 7% of patients due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the most common ARs (≥20%) were rash (72%), IRRs (59%), fatigue (51%), nail toxicity (45%), nausea (45%), constipation (39%), edema (36%), stomatitis (35%), decreased appetite (31%), musculoskeletal pain (30%), vomiting (25%), and COVID-19 (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (49%), decreased white blood cells (42%), decreased lymphocytes (28%), decreased platelets (17%), decreased hemoglobin (12%), decreased potassium (11%), decreased sodium (11%), increased alanine aminotransferase (3.9%), decreased albumin (3.8%), and increased gamma-glutamyl transferase (3.1%).In MARIPOSA-2, serious ARs occurred in 32% of patients, with those occurring in >2% of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each).In PAPILLON (n=151), the most common ARs (≥20%) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.RYBREVANT® as a Single AgentIn CHRYSALIS (n=129), the most common ARs (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).Serious ARs occurred in 30% of patients, with those occurring in ≥2% of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.LAZCLUZE® DRUG INTERACTIONSAvoid concomitant use of LAZCLUZE® with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.Please see full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE®.cp-491009v2About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT®-based regimens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

###* Joel W. Neal, M.D., Ph.D., has served as a consultant to Johnson & Johnson; he has not been paid for any media work.† Once monthly after weekly injections from weeks 1-4.‡ The NCCN content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.§ See the NCCN Guidelines for detailed recommendations, including other treatment options.|| The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.Source: Johnson & Johnson1 Neal JW, et al. Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced NSCLC: Updated results from the CHRYSALIS-2 study. Presented at: 2026 ASCO Annual Meeting; 2026; Chicago, IL.
2 Tomasini P, Wang Y, Li Y, et al. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. J Clin Oncol. 2026;44(1):54-65. doi:10.1200/JCO-24-02835
3 Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17(3):237-245. doi:10.1080/15384047.2016.1139235
4 Patil T, Mushtaq R, Marsh S, et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non-small-cell lung cancer. Clin Lung Cancer. 2020;21(3):e191-e204. doi:10.1016/j.cllc.2019.11.008
5 Fabrizio FP, Attili I, de Marinis F. Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art. Cancers. 2024; 16(7):1331. https://doi.org/10.3390/cancers16071331
6 Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. doi:10.1016/S1470-2045(15)00026-1
7 GILOTRIF® (afatinib tablets), for oral use [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc.; 2022.
8 Moores SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833
9 Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056. doi:10.1158/1535-7163.MCT-20-0071
10 Yun J, Lee SH, Kim SY, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020;10(8):1194-1209. doi:10.1158/2159-8290.CD-20-0116
11 Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer. Lung Cancer. Published online May 22, 2026. doi:10.1016/S0169-5002(26)00466-6.
12 RYBREVANT® Prescribing Information. Horsham, PA: Janssen Biotech, Inc.
13 ClinicalTrials.gov. A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (CHRYSALIS-2). Available at: https://clinicaltrials.gov/ct2/show/NCT04077463. Accessed May 2026.
14 The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed May 2026.
15 American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed May 2026.
16 Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.
17 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
18 Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.
19 Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
20 Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.
21 Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.
22 American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed May 2026.
23 Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.
24 Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65.
25 Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.
26 Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
27 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2026 © National Comprehensive Cancer Network, Inc. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed May 2026.
28 Cho BC, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: Results From LASER301. J Clin Oncol. 2023;41(26):4208-4217.
29 LAZCLUZE® Prescribing Information. Horsham, PA: Janssen Biotech, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer-302785924.htmlSOURCE Johnson & Johnson

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and CFO, and head of MetLife Investment Management, will participate in a fireside chat at the Morgan Stanley US Financials Conference on Wednesday, June 10, 2026, at 1:00 pm ET.

The live webcast can be listened to by clicking here. Please visit the link at least 15 minutes in advance to allow time to register or sign in.

If you miss the remarks, you can access a replay at the above link, which will be available until June 17, 2026 at 11:59 pm ET.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

More News From MetLife, Inc.